Contact
Cap Sigma - ZAC Euromédecine II, 1682 Rue de la Valsière
34790 Grabels
France
Business development director
About us
Mabqi is a biotechnology company specializing in the discovery and development of human therapeutic antibodies.
Through LiteMab© Antibody Discovery Studio, the company empowers next-generation antibody innovation with an advanced suite of synthetic libraries - encompassing billions of highly developable, functional human antibodies — with an AI-driven dual-display workflow.
This cutting-edge platform accelerates the discovery of breakthrough therapeutics, including monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), pH-sensitive antibodies, and cutting-edge immunotherapy formats.
The company is also building a proprietary portfolio of first-in-class and best-in-class antibodies with high therapeutic potential in oncology
More information: https://mabqi.com/antibody-pipeline-oncology/
Business offer
· Antibody discovery:
- in vitro selection of readily-developable and functional antibodies with high specificity and affinities.
This approach is suited for virtually any targets including ion channels, GPCRs, peptides, proteins, peptide-MHC complexes.
- Comprehensive antibody hits’ characterization and functional validation.
· pH-sensitive antibody discovery to target the tumor acidic micro-environment, reduce on-target / off-tumor toxicity, or use for recycling strategies.
· Antibody maturation (based on a parental antibody lead) to improve binding affinity, specificity and interspecies cross-reactivity, enhance developability, to optimize therapeutic potency and functionality such as pH-sensitivity or internalization.
Activities
- Therapeutic Product
- Service
- Cardiology
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Inflammation
- Hit discovery
- Screening & Identification
- Therapeutic libraries
- Bioinformatics prediction & analysis
- Immunotherapy lead generation
- Binding & Affinity
- Potency & Specificity
- Epitope mapping
- Functional effects
- ADCC, ADCP & CDC
- Antigen density target
- Internalization
- Immunotherapy lead optimization
- Engineering
- ADC
- Multi-, bispecific
- Antibody humanization
- Affinity maturation
- Proof of concept
- in-vitro & ex-vivo models
